Skip to main content

Table 3 Overall antimicrobial susceptibility and trends for 2014, 2016 and 2018

From: Neonatal sepsis in a tertiary unit in South Africa

Antimicrobials 2014
n (%)
2016
n (%)
2018
n (%)
Total study period - n (%) Episodes omitteda (n)
Gram positive organisms
Staphylococcus aureus
  Cloxacillin 0/4 (0.0) 4/10 (40.0) 1/10 (10.0) 5/24 (20.8) 0
  Vancomycin 3/3 (100.0) 10/10 (100.0) 9/9 (100.0) 22/22 (100.0) 2
CoNS
  Cloxacillin 5/100 (4.5) 13/114 (10.4) 14/139 (11.1) 32/363 (8.8) 0
  Vancomycin 11/11 (100.0) 14/14 (100.0) 21/21 (100.0) 46/46 (100.0) 317
Enterococcus species
  Ampicillin 6/18 (33.3) 7/17 (41.2) 11/29 (37.9) 24/64 (37.5) 0
  Vancomycin 18/18 (100.0) 17/17 (100.0) 29/29 (100.0) 64/64 (100) 0
Gram negatives organisms
Enterobacterales
  Amikacin 37/41 (90.2) 30/43 (38.6) 27/33 (57.6) 94/117 (80.3) 1
  Cefotaxime 10/41 (24.4) 13/43 (30.2) 17/33 (51.5) 40/117 (34.2) 1
  Ceftazidime 10/40 (25.0) 13/43 (30.2) 18/33 (54.5) 41/116 (35.3) 2
  Ciprofloxacin 22/41 (53.7) 31/44 (70.5) 20/32 (62.5) 73/117 (62.4) 1
  Ertapenem 33/34 (97.1) 34/38 (89.5) 26/31 (83.9) 93/103 (90.3) 15
  Gentamicin 10/39 (25.6) 17/44 (38.6) 19/33 (57.6) 46/116 (39.7) 2
 Imipenem 34/34 (100.0) 39/43 (90.7) 28/33 (84.8) 101/110 (91.8) 8
  Meropenem 40/41 (97.6) 39/43 (90.7) 28/33 (84.8) 108/11792.3 1
  Piperacillin-Tazobactam 23/41 (56.1) 21/39 (53.8) 17/30 (56.7) 61/11055.5 8
Gram-negative non-fermenters
  Amikacin 16/21 (76.2) 9/17 (52.9) 1/15 (6.7) 26/53 (49.1) 11
  Ceftazidime 1/21 (4.8) 7/21 (33.3) 1/16 (6.3) 9/59 (15.3) 6
  Ciprofloxacin 5/22 (22.7) 6/22 (27.3) 1/17 (5.9) 12/61 (19.7) 3
  Gentamicin 2/22 (9.1) 3/17 (17.6) 1/13 (7.7) 6/52 (11.5) 12
  Imipenem 2/16 (12.5) 5/20 (25) 0/16 (0.0) 7/52 (13.5) 12
  Meropenem 5/22 (27.2) 5/20 (25.0) 0/16 (0.0) 10/58 (17.2) 6
  Piperacillin-Tazobactam 4/22 (18.2) 4/20 (20.0) 1/16 (6.3) 6/58 (15.5) 6
Fungal isolates
  Fluconazole 2/9 (22.5) 7/10 (70.0) 18/12 (54.8) 17/31 (54.8) 0
  1. aOmitted due to missing data